Raffi F, Taburet A M, Ghaleh B, Huart A, Singlas E
Hôpital Universitaire, Hotel-Dieu, Nantes, France.
Antimicrob Agents Chemother. 1993 Sep;37(9):1777-80. doi: 10.1128/AAC.37.9.1777.
The diffusion of foscarnet into cerebrospinal fluid (CSF) was studied in 27 patients with AIDS. Foscarnet was administered intravenously at various dosages at 12-h intervals. Concentrations in plasma and CSF at the end of foscarnet infusion or 1, 3, 5, 6, and 12 h after infusion were determined by high-performance liquid chromatography. Thirty-seven samples were obtained. The median concentration of foscarnet in CSF was 80 mumol/liter (range, 0 to 500 mumol/liter). The CSF foscarnet concentration was greater than the 50% inhibitory concentration for human immunodeficiency virus type 1 and was equal to or greater than the 50% inhibitory concentration for cytomegalovirus in most cases. The penetration of foscarnet into CSF, as expressed by the ratio of the concentration in CSF to the simultaneous concentration in plasma, ranged from 0 to 3.4 (median, 0.27) and was highly correlated with the presence of cells within CSF and the length of foscarnet therapy. Good diffusion of foscarnet in CSF allows evaluation of this drug in central nervous system cytomegalovirus and human immunodeficiency virus infections in patients with AIDS.
对27例艾滋病患者进行了膦甲酸钠向脑脊液(CSF)中的扩散研究。膦甲酸钠以不同剂量每隔12小时静脉给药一次。通过高效液相色谱法测定膦甲酸钠输注结束时或输注后1、3、5、6和12小时血浆和脑脊液中的浓度。共获得37个样本。脑脊液中膦甲酸钠的中位数浓度为80微摩尔/升(范围为0至500微摩尔/升)。在大多数情况下,脑脊液中膦甲酸钠浓度高于人类免疫缺陷病毒1型的50%抑制浓度,且等于或高于巨细胞病毒的50%抑制浓度。膦甲酸钠向脑脊液中的渗透,以脑脊液中浓度与同时期血浆中浓度的比值表示,范围为0至3.4(中位数为0.27),且与脑脊液中细胞的存在以及膦甲酸钠治疗时间高度相关。膦甲酸钠在脑脊液中的良好扩散使得能够在艾滋病患者的中枢神经系统巨细胞病毒和人类免疫缺陷病毒感染中评估这种药物。